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Abstract
Background: Inosine triphosphatase (ITPase) is encoded by the polymorphic gene ITPA and maintains low intracellular
levels of the inosine nucleotides ITP and dITP. The most frequently reported polymorphisms are ITPA c.94C.A (rs 1127354)
and ITPA c. 124+21 A.C (rs7270101). Some nucleoside-analogues used in the treatment of HIV-seropositive (HIV+) patients
are potential substrates for ITPase. Therefore, the frequency of ITPA SNPs and ITPase activity were studied in a population of
HIV+-patients.
Methods: The study population consisted of 222 patients, predominantly Caucasian males, .95% using HAART. Erythrocyte
ITPase activity was determined by measuring the formation of IMP from ITP. ITPA genotype was determined by sequencing
genomic DNA. Distribution of ITPase activity, genotype-phenotype correlation and allele frequencies were compared to 198
control subjects. The effect of nucleoside analogues on ITPase activity was studied using lymphoblastic T-cell cultures and human
recombinant ITPase. Enzyme kinetic experiments were performed on erythrocyte ITPase from HIV+ patients and controls.
Results: No difference was observed in the allele frequencies between the HIV+-cohort (6 HAART) and the control
population. HIV+ carriers of the wild type and ITPA c.94C.A had significantly lower ITPase activities than control subjects
with the same genotype (p,0.005). This was not observed in ITPA c. 124+21 A.C carriers. Nucleoside analogues did not
affect ITPase activity in cell culture and human recombinant ITPase. Conclusion: ITPA population genetics were identical in
HIV+ and control populations. However, the majority of HIV+-patients had decreased erythrocyte ITPase activity compared
to controls, probably due to decreased amounts of ITPase protein. It seems unlikely that ITPase activity is decreased due to
nucleoside analogues (HAART). Long-term effects of HIV-infection altering ITPase protein expression or stability may explain
the phenomenon observed.
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Introduction
ITPA (OMIM 147520) encodes the enzyme inosine-59-triphos-
phate pyrophosphohydrolase (inosine-59-triphosphatase, ITPase),
which is a housekeeping enzyme that controls the intracellular
concentration of (deoxy)inosine-59-monophosphate, (d)IMP, by
catalysing the conversion of ITP and dITP to IMP and dIMP,
respectively [1]. ITPase belongs to a family of nucleoside
triphosphatase proteins that scavenge non-canonical nucleoside
triphosphates that are potentially cyto- or genotoxic [2].
In humans, ITPA is a polymorphic gene of which multiple single
nucleotide polymorphisms (SNPs) have been described. However,
two SNPs, i.e. ITPA c.94 C.A (rs 1127354) and ITPA c. 124+21
A.C (rs 7270101) are found in all populations over the world with
varying frequencies [3]. Both SNPs are associated with reduced
ITPase activity [4,5], the ITPA c.94 C.A substitution causes both
an amino acid substitution (P32T) and causes missplicing whereas
ITPA c. 124+21 A.C causes missplicing [6].
ITPase is expressed in all human tissues and has the highest
mRNA expression in endocrine organs [7]. To this day, no overt
causal clinical entity has been associated with deficiency of ITPase
[8,9,10]. However, ITPA genotype may influence the clinical
outcome of certain clinical conditions [11]. Until recently,
pharmacogenetic consequences of ITPA have solely been impli-
cated for the thiopurine drugs azathioprine and 6-mercaptopurine
[4,12]. Although the mechanism is still not fully elucidated, there is
a tendency towards consensus that ITPA polymorphisms cause
adverse drug reactions (ADR) in thiopurine therapy. More
recently, ITPA polymorphisms have been associated with a
protective effect against ribavirin induced anaemia in patients
with hepatitis C [13]. Some nucleoside-analogues used in the
treatment of HIV-seropositive (HIV+) patients are potential
substrates for ITPase. Therefore, we performed a study in which
the ITPase activity and ITPA genotype were determined in HIV+
patients. The ITPase activities were compared to established
genotype-specific reference values. In addition, in vitro experiments
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were used to study effects of nucleoside analogue reverse
transcriptase inhibitors on ITPase activity. The present paper
focuses on an unexpected phenomenon we observed in our cohort
of HIV-infected patients that raises deeper and more fundamental
questions on the biological role of ITPase and the effect of HIV on
human nucleotide metabolism.
Results
Patients and control population characteristics
The characteristics of the cohort of HIV+ patients are shown in
table 1. Compared to the control population, the HIV+ patients
were slightly younger than the control subjects and were
predominantly male. The majority of patients were using HAART
(212 out of 222) and had HIV RNA ,40 copies/ml. A total of 15
patients had a sub-normal whole-blood haemoglobin concentra-
tion (,8.2 mmol Hb/l for men and,7.3 mmol Hb/l for women).
The anaemic patients were 9 men with Hb 6.4–8.1 mol/l and 6
women with Hb 4.6–7.2. The HIV status of the control population
is unknown. Assuming an incidence of HIV infection of 0.1% in
the Dutch population [14], it cannot be excluded that one HIV+
individual was included in the control population. This would not
change the results of our analysis.
ITPA genotyping, population genetics and laboratory
parameters
In order to determine the allele frequencies of the two
prominent ITPA polymorphisms, the ITPA genotype was deter-
mined in all samples. The allele frequencies at positions ITPA c.94
and ITPA c.124+21 A.C in both populations were in Hardy-
Weinberg equilibrium (table 2).The calculated allele frequencies
were in accordance with previous reports for Caucasian
populations [3,5,15]. Although at the ITPA c.94 locus there
appeared to be a slightly higher incidence of adenosine residues in
the HIV+ population, this was not statistically significant.
Table 3 shows the ITPA genotypes identified in the HIV+-
population. In accordance with what would be expected from the
allele frequencies, most patients were carriers of the wild-type
genotype, followed by ITPA c.121+21 A.C and ITPA c.94 C.A
carriers, respectively. Only 7 patients had a genotype different
from the mentioned genotypes.
No statistically significant relation between ITPA genotype and
HIV RNA copy numbers, CD4+ lymphocytes count or use of
antiretroviral therapy was observed (Table 3). Neither was a
statistical significant correlation observed between ITPase activity,
HIV RNA copy numbers, and CD4+ lymphocytes count (data not
shown) No association between ITPA genotype, or ITPase activity
with whole-blood haemoglobin content could be demonstrated.
The haemoglobin concentration in the lysates prepared from the
isolated erythrocytes was independent of whole-blood haemoglo-
bin content and ITPA genotype.
ITPA genotype and ITPase activity
No difference in ITPase activity could be shown for gender in
the control population as well as in the HIV+ population (data not
shown). The mean erythrocyte ITPase activity in the HIV+
population (3.5561.69 mol/(mol Hb ? h)) was significantly lower
than in the control population (4.5762.27 mol/(mol Hb ? h)),
p,0.001. Purine nucleoside phosphorylase (PNP) activity deter-
mined as reference enzyme activity, was within the reference range
(71.366.7, 50–85 mol/(mol Hb ? h)) in all HIV+ patients
(78.6611.1, 50–128 mol/(mol Hb ? h)).
The ITPase activity of HIV+ individuals carrying either ITPA
wild type or ITPA c.94 C.A was 20% lower than that of
individuals with the same genotype from the control population
(p,0.001). (table 4). The most pronounced decrease in ITPase
activity was found in HIV+ heterozygous carriers of ITPA c.94
C.A. Instead of the expected 26% residual activity, the observed
residual activity was 16% when compared to the HIV+ and
control population wild type activities. Moreover, HIV+ carriers of
ITPA c.94 C.A had 40% less ITPase activity than controls with
the same genotype. Because in homozygous state the ITPA c.94
C.A polymorphisms leads to null activity in erythrocytes the
effect could not be assessed for this genotype. The ITPase activity
of both heterozygous and homozygous carriers of ITPA c.124+21
A.C did not differ significantly between both populations.
The effect of nucleoside analogues on ITPase activity
Because the vast majority of the patients in the cohort were
treated with HAART, one might argue that the nucleoside
Table 1. Patient and control subject characteristics.
HIV+ patients
Reference population
ITPase activity/genotype Reference population genotyping Genotype specific reference values
N 212 98 98 575
Source MUMC HIV+
clinic
General hospital
population (a)
Anonymous samples from
healthy subjects (b)
Pharmacogenetic diagnostic
services (c)
Male/female 185/27 49/49 49/49 -
Median age (years) 47 58
Predominant ethnicity Caucasian Caucasian Caucasian Caucasian
Control populations consisted of (a) patients from the general hospital population, (b) healthy control subjects and (c) predominantly patients with inflammatory bowel
or pulmonary disease.
doi:10.1371/journal.pone.0030175.t001
Table 2. ITPA allele frequencies in control and HIV+-
populations.
Position Reference sequence Nucleotide
Control
n =182
HIV
n=203
ITPA c.94 rs 1127354 C 0.951 0.943
A 0.049 0.057
ITPA c.124+21 rs 7270101 A 0.887 0.867
C 0.113 0.133
doi:10.1371/journal.pone.0030175.t002
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analogues in their circulation might have had an inhibitory effect
on ITPase activity. The potential inhibitory effect of nucleotide or
nucleobase analogues on ITPase was studied using human
recombinant ITPase (figure 1A). After pre-incubation of 0.2 mg
of hrITPase with 10 mM of either ziduvodine (AZT), zalcitabine
(ddC), stavudine (d4T), dideoxyadenosine (ddA), didanosine (ddI),
tenofovir (TDF), abacavir (ABC), lamivudine (3TC), 6-mercapto-
purine (6MP), cytarabine (araC), or gemcitabine (dFdC) no
significantly altered ITPase activity was observed.
The effect of exposure to nucleoside analogues on ITPase
activity was assessed by incubating MOLT-3 lymphoblastic T-cells
for 18 hrs with 0–100 mM of the panel of analogues. MOLT-3
cells had the wild type genotype for ITPA. The cytotoxic analogues
araC and dFdC induced a significant decrease of ,10% of ITPase
activity. ITPase activity was not affected by the antiretroviral
compounds and 6-MP (figure 1B, displaying the results of
incubation with 10 mM analogue).
Discussion
The nucleotide triphophosphates of nucleoside-analogue re-
verse-transcriptase inhibitors that are an integral part of HAART,
are potential substrates for ITPase [1]. That prompted us to study
the frequency of ITPA polymorphisms and the erythrocyte ITPase
activity in a cohort of HIV-seropositive patients. We describe here
the unexpected phenomenon that ITPase activity is reduced in the
majority of patients infected with HIV.
The control population and HIV+ populations were not
statistically different with respect to population genetics, and the
allele frequencies were as previously reported for Caucasian
populations [3,5,15]. This makes a hypothetical predisposition of
carriers of ITPA polymorphisms to sustained HIV infection
unlikely. Because the enzyme activity is a measure for the amount
of functional ITPase protein present, it seems probable that the
erythrocytes of HIV+ individuals contained less functional ITPase
protein than those of controls. As of yet, it is unclear whether less
ITPase protein was synthesised or that the stability of the protein
was reduced. It is also possible that ITPase enzyme activity might
be decreased in circulating red cells due to an aging erythrocyte
population as a result of decreased bone marrow red cell
production in HIV patients.
The decreased ITPase activity did not appear to be secondary
to anaemia, as only ,7% of patients were mildly anaemic and in
these patients ITPase activity was independent of whole-blood
haemoglobin concentration. Although ITPA SNPs appear to
prevent ribavirin induced anaemia in patients with hepatitis C
[13], in our HIV+-cohort anaemia was not associated with any of
the ITPA SNPs. However, since our HIV+ cohort was relatively
small it seems premature to draw a final conclusion about the
relationship between ITPA polymorphisms and anaemia in HIV+
patients using antiretroviral therapy.
To determine whether or not use of HAART may lead to
decreased ITPase activity, we explored the possibility that ITPase
Table 3. HIV patient parameters stratified by ITPA genotype.
ITPA genotype All patients Wild type
c.94C.A
heterozygote
c.94C.A
homozygote
c.124+21 A.C
heterozygote
c.124+21 A.C
homozygote
c.94C.A and
c.124+21 A.C
heterozygote
N 222 136 19 1 60 3 3
Male/Female 191/31 117/19 13/6 1/0 55/5 3/0 2/1
Median age (years) 47 47 45 41 46 48 42
Range (years) 21–79 21–79 24–62 - 27–65 47–63 36–75
HIV RNA ,40 copies/ml 183 107 15 1 54 3 3
HIV RNA .40 copies ml 39 29 4 0 6 0 0
Mean VL 2595 11201 4322 - 6750 - -
Mean CD4+ lymphocytes
6106/L
574 583 541 416 723 389 863
Using HAART 212 128 18 1 59 3 3
doi:10.1371/journal.pone.0030175.t003
Table 4. ITPase activities stratified by genotype, compared between control and HIV+-population.
Control HIV+
ITPA genotype ITPase activity ± SD % activity** HIV+ ITPase activity ± SD % activity**
Wild type 5.3861.52 100 4.3161.39* 80.1
c.94 C.A heterozygote 1.4360.55 26.6 0.8660.23* 16.0
c.124+21 A.C heterozygote 2.6160.66 48.5 2.6760.69 49.6
c.94C.A homozygote 0.0060.05 0.03
c.124+21 C.C homozygote 1.8160.19 33.6 1.9960.73 37.0
ITPase activity in mol IMP/(mol Hb6 h).
*p,0.001.
**% activity wild type: residual ITPase activity relative to wild type ITPase activity.
doi:10.1371/journal.pone.0030175.t004
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activity was decreased due to direct inhibition of the enzyme or by
indirect effects of nucleoside analogues. We observed no direct
effects of nucleoside analogue reverse transcriptase inhibitors
either in cultured cells MOLT-3 cells exposed to these compounds
or in vitro by addition of nucleoside analogues to the ITPase
enzyme assay reaction mixture. This does not, however, exactly
mimic the situation that occurs in patients receiving long-term
treatment with HAART. Unfortunately, few HIV+ patients were
not using antiretroviral therapy and firm conclusions cannot be
drawn.
A shortage of nucleotide triphosphates, which may either be caused
by mitochondrial dysfunction as seen in patients with HIV, or in
theory by competition for phosphate esters between natural substrates
and therapeutic nucleoside analogues, may cause a down-regulation of
ITPase expression as a means of conserving triphosphate esters. This
leaves unexplained why in case of hetero- or homozygosity of ITPA
c.124+21 A.C the expression remained unaltered.
Interestingly, Jacobsson and colleagues described decreased
level of thymidine kinase activity in lymphocytes of HIV+ patients
and a generalised decrease in peripheral blood mononuclear cell
thymidylate kinase was observed in HIV-infected individuals
[16,17]. Since only a fraction of all PBMC is infected with HIV,
these authors concluded that this phenomenon was a generalised
effect. In addition, HIV-infected T-lymphocytes were unable to
biosynthesise ribonucleotides upon stimulation and consequently
died [18]. Despite the fact that these studies were performed in
white blood cells, these observations show intriguing parallels with
our observation in eryhtrocytes, and suggest the possibility that
there may exist a common mechanism by which HIV interferes in
nucleotide metabolism.
Figure 1. The effect of nucleoside analogues on ITPase activity. A: The effect of the addition of nucleoside analogues (10 mM) on the activity
of hrITPase (2 mg). B: ITPase activity of MOLT-3 cells after 18 hr of incubation with 10 mM of the nucleoside analogues indicated; ziduvodine (AZT),
zalcitabine (ddC), stavudine (d4T), dideoxyadenosine (ddA), didanosine (ddI), tenofovir (TDF), abacavir (ABC), lamivudine (3TC), 6-mercaptopurine
(6MP), cytarabine (araC), gemcitabine (dFdC)* p,0.05.
doi:10.1371/journal.pone.0030175.g001
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With respect to the correlation between ITPA genotype and
ITPase activity, the effect of the ITPA c.94 C.A polymorphism on
ITPase activity is thought to be an accumulation of catastrophic
events. ITPA is transcribed into three mRNA transcripts, of which
the full length transcript is the major gene product for the wild
type genotype. In the ITPA c.94 C.A carriers and homozygotes a
transcript lacking exons 2 and 3 is prominent [6], resulting in less
full length mRNA encoding the protein. Moreover, the mutation
codes for an amino acid substitution, giving rise to a mutated
protein having reduced to normal ITPase activity and, more
relevant, decreased stability [19,20]. It may be speculated that
HIV itself or a factor secondary to HIV infection or treatment also
affects expression of ITPA, activity or stability of the protein.
In conclusion, HIV-infected individuals carrying either ITPA
wild type or c.94 C.A have reduced erythrocyte ITPase activity,
most likely due to decreased amounts of active protein being
present. This phenomenon was not observed in patients carrying
ITPA 124+21 A.C. Long-term effects of HIV-infection altering
protein expression or stability might explain the phenomenon
observed.
Materials and Methods
Patients and control subjects
HIV-seropositive patients, visiting the HIV outpatient clinic of
the Maastricht University Medical Centre (MUMC) aged 18 years
and older were eligible for inclusion in the study. All consecutive 222
patients asked for participation consented. A reference population
consisting of 98 anonymous samples from the general hospital
population was used for determination of both ITPase activity and
ITPA genotyping. Together, with another 98 anonymous DNA
samples from healthy donors reference population genetics were
determined. The two subpopulations proved to be statistically
similar. Genotype specific erythrocyte ITPase reference values were
determined using samples of which ITPase activity and ITPA
genotype were known. This included the anonymous cohort and
data obtained through our diagnostic pharmacogenetic services for
patients with e.g. inflammatory bowel disease, or inflammatory
pulmonary disease [21,22]. All control samples were used according
to the code for proper use of human tissue as formulated by the
Dutch Federation of Medical Scientific Societies. The study was
approved by the Medical Ethics Committee of the MUMC and all
patients signed written informed consent.
Materials
Full length recombinant human ITPase (hrITPase) from an
E.coli expression system was purchased from Abnova (Bioconnect,
Huissen, The Netherlands). Nucleoside analogues were obtained
from Sigma (Zwijndrecht, The Netherlands). All other chemicals
were of the highest grade. HPLC separation were performed using
a Supelcosil LC-18S column (Sigma, Zwijndrecht, The Nether-
lands), with an Alliance Separation system (Waters, Etten-Leur,
The Netherlands) equipped with a Jasco Multi-Wavelength
detector (Jasco Benelux, Ijsselstein, The Netherlands). Data were
analysed with Totalchrom data acquisition software (Perkin-
Elmer, Groningen, The Netherlands). Haemoglobin was mea-
sured on a Coulter LH-750 haematology analyser (Beckman
Coulter, Mijdrecht, The Netherlands).
Cell culture and handling
MOLT-3 cells were obtained from the American Type Culture
Collection (Manassas, VA). The cells were maintained in
Dulbecco’s Modified Eagles Medium, supplemented with 10%
foetal calf serum, 2 mM L-Glutamine, 50 IU/ml penicillin and
0.2 mg/ml gentamycin at 37uC in humidified air with 5% CO2.
Nucleoside analogues were added to the medium and after the
appropriate incubation time the cells were harvested and washed
by centrifugation.
Enzyme activity assays
The ITPase activity in erythrocytes was determined as
previously described [23]. Briefly, 25 ml of erythrocyte lysate,
corresponding with approximately 45 nmol Hb, was incubated
with 2.00 mM ITP, 50 mM MgCl2 in 100 mM Tris pH 7.4 in a
final volume of 200 ml. The formation of IMP from ITP was
quantified by using ion-pair HPLC method with UV detection.
ITPase activity was expressed as moles of IMP formed from ITP in
one hour per mol haemoglobin.
In assays with hrITPase, 0.2 mg of hrITPase was incubated with
10 mM of the appropriate nucleoside analogue under the same
conditions as the routine ITPase assay.
The Purine nucleoside phosphorylase (PNP) activity was mea-
sured as a control assay for lysate quality. It was determined by
incubating 15 ml of a ten-fold diluted erythrocyte lysate, correspond-
ing with approximately 4.5 nmol Hb, with 7.5 mM inosine in
100 mM NaPi buffer pH 6.6 for 30 minutes at 37uC. Further
sample handling and activity measurement using chromatographic
separation of the compounds of interest was as described above. PNP
activity was expressed as moles of hypoxanthine formed from inosine
in one hour per mol haemoglobin.
DNA isolation and ITPA Genotyping
Genomic DNA was isolated from buffy coats using the Wizard
Genomic DNA purification kit (Promega, Madison, WI). All DNA
samples were genotyped for the polymorphisms ITPA c.94C.A
(p.Pro32Thr, rs1127354) and c.124+21A.C (rs7270101). Wild
type (wt) genotype was defined as no polymorphisms being
detected at both positions. M13-tagged (underlined) primers
forward 59-TGTAAAACGACGGCCAGTCTTAGGAGATGG-
GCAGCAG and 59-CAGGAAACAGCTATGACCCACAGAA-
AGTCAGGTCACAGG reverse were used in a PCR reaction of
10 ml. The resulting 241 bp PCR product was purified and
directly sequenced in both directions using the Big Dye
Terminator kit and analysed on an ABI 3720 Genetic Analyzer
(Applied Biosystems, Carlsbad, CA). The sequence was aligned
with ITPA reference sequence NM_033453.2 and genotypes were
determined.
Statistical analyses
Data are presented as mean values 6 SD. ITPase activities in
groups were compared using independent t-test and one-way
Anova. Allele frequencies were compared using Chi-square test.
Paired samples were analysed using Student’s t-test. P-val-
ues,0.05 were considered to be significant.
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